FDAnews
www.fdanews.com/articles/73483-adventrx-presents-response-data-for-enrollment-in-cancer-trial

ADVENTRX PRESENTS RESPONSE DATA FOR ENROLLMENT IN CANCER TRIAL

June 20, 2005

Adventrx Pharmaceuticals has announced response data from all 48 measurable patients in its 50-patient Phase II trial with CoFactor and 5-fluorouracil (5-FU) as a first-line treatment for metastatic colorectal cancer.

CoFactor is Adventrx's biomodulator designed to enhance the effects of the widely used cancer drug, 5-FU. A poster of these results was presented at the 7th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Sixty-five percent, or 31 patients, treated with CoFactor and 5-FU achieved clinical benefit, defined as tumor response or stable disease following study therapy.